drugset / Trial / NCT04480125
Azacitidine Combined With Chidamide in the Treatment of Newly Diagnosed PTCL Unfit for Conventional Chemotherapy
NaSingle-groupOpen-labelTreatment
Summary
This prospective, open-label, single-arm study will evaluate the efficacy and safety of azacitidine in combination with chidamide in treatment of newly diagnosed peripheral T-cell lymphoma unfit for conventional chemotherapy.
Timeline
- Start
- 2020-06-20
- Primary completion
- 2022-06-20
- Completion
- 2024-06-20
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Azacitidine | Other / unclassified | 100 mg | Intravenous |
| Subject | Tucidinostat | Small molecule | 30 mg | Oral |